Tensha Therapeutics

Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic regulators of gene expression, for the treatment of cancer and other serious diseases. The company’s programs are based on discoveries from the laboratory of Dr. James Bradner at the Dana-Farber Cancer Institute, which has best-in-class, potent small molecule BET bromodomain inhibitors. The company’s lead program aims to treat patients with BRD4-NUT midline carcinoma, acute myeloid leukemia, multiple myeloma, and other conditions. Tensha is a focused company funded by HealthCare Ventures.